This difference may be due to the lack of available and effective anti-tumor T cell response that could be enhanced by Arg and anti-PD-L1 antibodies within tumors, and to some extent limit the interpretation and expectation of this combined therapy towards potential clinical use. This evidence concerns the gene CD274 and neoplasm.